NCT06377774 is a clinical trial of No intervention in this study in Acute-On-Chronic Liver Failure, sponsored by Nanfang Hospital, Southern Medical University.

Who is sponsoring NCT06377774?

NCT06377774 is sponsored by Nanfang Hospital, Southern Medical University.

What drugs are being tested in NCT06377774?

Interventions in NCT06377774: No intervention in this study.

What condition does NCT06377774 study?

NCT06377774 studies Acute-On-Chronic Liver Failure.

Is NCT06377774 still recruiting?

NCT06377774 is currently not yet recruiting. Last updated 22 April 2024.

Last reviewed 2024-04-22 · How we verify

NCT06377774

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Optimize Therapeutic Procedures of DPMAS in ACLF Patients: a Prospective, Sigle Arm and Multicenter Study

Not yet recruiting Last updated 22 April 2024

What this trial tests

trial testing No intervention in this study in Acute-On-Chronic Liver Failure in 2,000 participants. Not yet recruiting.

Timeline

1 May 2024

Primary endpoint
30 March 2025

1 February 2026

Quick facts

Lead sponsor	Nanfang Hospital, Southern Medical University
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	1 May 2024
Primary completion	30 March 2025
Estimated completion	1 February 2026

Drugs / interventions tested

No intervention in this study

Conditions studied

Acute-On-Chronic Liver Failure — all drugs for Acute-On-Chronic Liver Failure →

Sponsor

Nanfang Hospital, Southern Medical University

Who can join

Adults 18 to 80, any sex, with Acute-On-Chronic Liver Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute-on-chronic liver failure (ACLF) is a life-threaten syndrome carrying high-short-term mortality raging 40% to 60% within 90 days in patients with chronic liver disease. Double plasma molecular adsorption system (DPMAS) is one of the available artificial liver support systems, which combines plasma filtration and two specific adsorption membranes dedicating to remove bilirubin and the middle molecular toxins respectively. The efficiency of DMPAS treatment in liver failure patients remains controversial. Previous study indicate that liver failure patients with DPMAS therapy improve the short-term mortality and prevent the diseases progression within 28 days (PADSTONE Study). Thus, this single-arm, multicenter and prospective study is to further validate and optimize the therapeutic procedures of DPMAS therapy in ACLF patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy of a novel artificial liver versatile plasma purification system in patients with acute-on-chronic liver failure.
Dai ZS, Zhang M, Deng YY, Zhou N, et al · · 2025 · cited 1× · PMID 40248372 · DOI 10.3748/wjg.v31.i14.103892

Verify or expand the search:

Other trials of No intervention in this study

Trials testing the same drug.

NCT06511492 — Longitudinal Surveillance of Rectal Colonization and Transmission by Resistant Bacteria in Acutely Decompensated Cirrhos · not yet recruiting
NCT04966923 — Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53 · completed
NCT03154203 — Non-Invasive Aortic Ambulatory Blood Pressure Monitoring for The Detection of Target Organ Damage in The Chinese Populat · unknown

Other recruiting trials for Acute-On-Chronic Liver Failure

Currently open trials in the same condition.

NCT07198854 — Risk Factors Affecting MSC Efficacy in ACLF Patients · recruiting
NCT06996392 — Phase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure · Phase 1 · active not recruiting
NCT06831565 — Comparison of Blood Products Required Using Two Different ROTEM Cut-offs Before Invasive Procedures in Cirrhosis and Acu · NA · recruiting
NCT06562803 — Efficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis · NA · recruiting
NCT06079021 — COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device · NA · recruiting

Other Nanfang Hospital, Southern Medical University trials

Trials by the same sponsor.

NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06377774 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
Last refreshed: 22 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06377774.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing